ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder
At the 36th European College of Neuropsychopharmacology congress (ECNP-2023)MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics,...